UROTHELIAL CARCINOMA

This is an early-stage study testing a new cell therapy for people with a specific type of bladder cancer that has come back after standard treatment. Researchers collect a patient's own immune cells from their tumor, grow more of them in a lab, and then put them back into the bl…

This early-stage study aims to find safe doses of a three-drug combination for treating advanced solid tumors in patients who also have kidney or liver problems. Researchers are testing a new drug called veliparib, given with two standard chemotherapy drugs, to see how the body p…

This study is testing new experimental drugs, given alone or with pembrolizumab (an immunotherapy drug), for people with advanced bladder cancer that has stopped responding to standard immunotherapy. It aims to find safer, more effective treatment options for this difficult-to-tr…

This study is testing whether giving an existing bladder cancer drug less frequently can still control the disease while potentially reducing side effects. The trial involves 60 adults with advanced bladder cancer who would normally receive standard treatment. Researchers want to…

This study is testing whether a new immunotherapy drug (BGB-A445) works better when combined with an existing one (tislelizumab) to treat advanced bladder, kidney, or skin cancers. It aims to see if the combination can shrink tumors and is safe for patients. The trial is for peop…

This study is testing a targeted drug called erdafitinib, both alone and combined with other treatments, for people with advanced bladder cancer that has spread or cannot be removed by surgery. The main goals are to find safe doses and see if these treatments can shrink tumors in…

This early-stage trial is testing a new drug called INBRX-106, both by itself and combined with an existing immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how …

This study is testing if adding a drug called durvalumab (an immunotherapy) to standard chemotherapy works better than chemotherapy alone for bladder cancer that has spread to nearby lymph nodes. The goal is to shrink the cancer more effectively before surgery. Patients will be r…

This early-stage study is testing whether combining two drugs—avelumab and AVB-S6-500—is safe for people with advanced bladder cancer that has spread or can't be surgically removed. The trial involves 19 participants who have already tried standard platinum-based chemotherapy. Re…

This early-stage trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for treating advanced small cell or neuroendocrine cancers of the bladder, urethra, or prostate. The study will enroll about 15 participants with cancer tha…

This study is testing a new combination of immune-boosting drugs for people with advanced cancers whose disease has progressed after treatment with standard immunotherapies like pembrolizumab or nivolumab. It aims to see if adding a drug called NAI to other treatments can help sh…

This study is testing whether adding a newer immunotherapy drug (atezolizumab) to standard chemotherapy (gemcitabine and cisplatin) is safe and effective for bladder cancer. It involves two groups of patients: those with cancer that has spread (metastatic) and those with cancer t…

This study is testing an investigational drug called TYRA300 for people with advanced bladder cancer and other solid tumors that have specific changes in a gene called FGFR3. The main goals are to find a safe and effective dose and to see if the drug can shrink or control the tum…

This was an early safety study for people with advanced bladder cancer that had spread. It aimed to test a combination of three drugs to see if they could control the cancer and were safe to use together. The study was withdrawn before any participants were enrolled.

This early-stage study is testing the safety and feasibility of new ways to deliver an immune-boosting drug called IMP321 to people with advanced solid tumors. Researchers are trying methods like injecting the drug directly into tumors or into the abdominal cavity, and combining …

This large, late-stage study is comparing a new two-drug combination (disitamab vedotin plus pembrolizumab) against standard chemotherapy for people with advanced bladder cancer that has spread. The goal is to see if the new combination works better to control the cancer and help…

This study is testing a new liquid treatment called UGN-103 for people with a specific type of early-stage bladder cancer that has a moderate risk of returning. The treatment is placed directly into the bladder once a week for six weeks. Researchers want to see if it can complete…

This study is testing a new treatment called cretostimogene to see if it can prevent intermediate-risk bladder cancer from returning after tumor removal surgery. About 367 participants will be randomly assigned to receive either the new treatment or standard observation with regu…

This study aimed to see if a targeted pill (erdafitinib) alone or combined with an immunotherapy drug (atezolizumab) could shrink aggressive bladder tumors before surgery. It was for patients whose cancer had grown into the muscle wall of the bladder and who could not receive the…

This early-stage trial is testing a new antibody drug called acasunlimab (GEN1046) for people with advanced solid tumors. The study first aims to find safe doses, then tests how well those doses work when given alone or combined with other cancer drugs. All 429 participants will …

This study is testing a combination of three drugs for people with advanced bladder cancer that has a specific genetic flaw called MTAP deficiency and has stopped responding to standard immunotherapy. The goal is to see if this new combination is safe and can help control the can…

This study is testing a new type of PET scan to see if it can more accurately show how far muscle-invasive bladder cancer has spread, compared to the standard CT or MRI scans used today. The scan uses a special imaging agent called 18F-fluciclovine, which may help doctors see can…

This study aims to find out which of two CT scan techniques is better at detecting cancers in the urinary tract, like bladder cancer. It will enroll 352 adults over 40 who have symptoms like blood in their urine or a past history of this cancer. Participants will be randomly assi…

This study aims to find new chemical markers in the blood and urine that could help detect kidney and bladder cancers. Researchers are collecting samples from 589 people, including those with these cancers and healthy individuals, to compare and identify reliable markers. The goa…

This early-phase study is testing a new imaging agent called 68Ga-FAPI-46 to see where it goes in the body of patients with various cancers. Researchers will give participants the tracer and then perform PET/CT scans to see how it collects in both normal and cancerous tissues. Th…

This study looks back at medical records of 360 Japanese patients with advanced bladder cancer who received avelumab maintenance therapy after initial chemotherapy. Researchers want to understand patient characteristics, treatment patterns, and survival outcomes. The study doesn'…

This study is observing how well the immunotherapy drug atezolizumab works and its safety for patients with advanced lung, bladder, or liver cancer in real-world medical settings. It involves over 2,700 patients who are already receiving this drug as part of their standard care. …